Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
about
Polysaccharide vaccines for preventing serogroup A meningococcal meningitisUse of licensed vaccines for active immunization of the immunocompromised hostProspects for vaccine prevention of meningococcal infectionPreventative strategies on meningococcal diseaseCovering all the Bases: Preclinical Development of an Effective Staphylococcus aureus VaccineDesigning vaccines for the twenty-first century societyDevelopment and Evaluation of a Multiplex Microsphere Assay for Quantitation of IgG and IgA Antibodies against Neisseria meningitidis Serogroup A, C, W, and Y PolysaccharidesPersistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.Vaccines against meningococcal disease: current and future technologies.Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.The meningococcus and mechanisms of pathogenicityHuman T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young childrenUpdate on meningococcal disease with emphasis on pathogenesis and clinical managementComparison of counter-current immunoelectrophoresis, latex agglutination, and radioimmunoassay in detection of soluble capsular polysaccharide antigens of Haemophilus influenzae type b and Neisseria meningitidis of groups A or C.Humoral immune responses to Neisseria meningitidis in children.Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis.Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.Incidence and prognosis of central nervous system infections in a birth cohort of 12,000 children.Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidisMeningococcal serogroup C conjugate vaccine.Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008Meningococcal disease in ScandinaviaMeningococcal disease: treatment and prevention.Prophylaxis in bacterial meningitis.Evolution of conjugate vaccines.Meningococcal glycoconjugate vaccines.Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.Serologic correlates of protection for evaluating the response to meningococcal vaccines.Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis BeltRecent developments in Neisseria meningitidis group A conjugate vaccines.Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins.Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis.
P2860
Q24244832-DB40E7A0-3FF2-4D95-96CA-AA907FD49BF6Q24533456-5FCBC15C-8E9F-40D2-8DA9-6FEA292D9DEFQ24537338-59A07606-0BDC-4F21-BD50-29A3D18E6456Q24676339-2E93685A-2B80-4026-892E-F46E32623561Q27008338-B31CD551-F92E-4911-8890-48232181ADE5Q27025703-3950C43A-983B-4311-9618-4C53218C1D89Q28397047-CAB4039D-1067-4E0D-AA9D-9EA1DA049613Q30210120-679ED5E4-FF3E-4DAD-8657-ED78941BC052Q30771493-57C96240-45BE-446D-B9D7-76077E623217Q33601899-6DA06292-DCEF-43C6-9A43-852AA1BCABE7Q33626434-5A49AC36-E270-47C4-88C7-DB5475016FDDQ33751297-9CF63ACD-CC02-4EEE-9D37-B5186A707496Q33754255-5ACC9EC7-FEA9-48C5-A7A9-33235419AAF5Q33767903-3B9F8FB7-0BE5-431D-8648-6AD646F29207Q33769150-21C5791B-DAB6-4434-99DC-CBD956DEB605Q33797264-988FF9CA-487C-4AEB-8D70-FF57C88B308CQ33812435-0DD60E6B-8994-428D-A866-28933CAA9490Q33846773-DB7B79F1-3CA5-436D-9F17-6110A621444DQ33867340-C9D6AF11-0636-45CC-B56F-9E118FC5F1F4Q33908993-7F8C9419-C906-4D23-B89E-F308CF3B55F9Q34002209-67CF8FAD-9412-4A5C-B798-D9CE724DA7B8Q34094054-05A3C4E1-85A3-4E56-965C-D16DA4E15C9FQ34189898-573318C4-B863-4326-BEB0-869B3CF84D9BQ34260060-0D38B6E8-15F7-43FD-9D5A-B423D7F7348EQ34482078-14FB4522-CC00-441B-A0A6-0E0AF3713FD8Q34533811-F0955084-CCB5-41EE-9A00-99BCB69EDA53Q34606343-9BE4B81E-807B-4232-B357-FAFC90643983Q34760360-3376C34A-A7C2-4807-AAC6-78035D1D4B6BQ35055030-6E38B739-4A81-473C-9A0B-4E0720FA3A37Q35115426-9B6C394D-DE82-45CE-B399-78C93C2166E9Q35193487-1C768AEF-CB44-4F68-9C92-91A73DA40E1AQ35194824-E76C0AEC-C9F6-4F46-BA5C-9B3CB227D70CQ35229074-07008EBC-F85D-4A05-811B-4F6F7F256916Q35648260-456A7C25-1737-47AC-B4E6-70BC57F1968AQ35783511-ADF237C6-5A51-4AD6-B085-9C0F0D2B1820Q35801994-ACDD52F2-879B-430C-852F-28D3FA6459C3Q35922578-9C6EF540-931A-44E2-9A0B-7F5E7375CF0AQ36065978-BF9421D6-C5B9-4BAA-AC62-EB9B0A41349CQ36181172-6BD8FCED-89C5-4F46-A87E-07B7A9E8B877Q36231457-ECA9A206-7A78-441B-B20C-476C942909E3
P2860
Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
description
1977 nî lūn-bûn
@nan
1977 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Clinical efficacy of meningoco ...... e months to five years of age.
@ast
Clinical efficacy of meningoco ...... e months to five years of age.
@en
Clinical efficacy of meningoco ...... e months to five years of age.
@nl
type
label
Clinical efficacy of meningoco ...... e months to five years of age.
@ast
Clinical efficacy of meningoco ...... e months to five years of age.
@en
Clinical efficacy of meningoco ...... e months to five years of age.
@nl
prefLabel
Clinical efficacy of meningoco ...... e months to five years of age.
@ast
Clinical efficacy of meningoco ...... e months to five years of age.
@en
Clinical efficacy of meningoco ...... e months to five years of age.
@nl
P2093
P1476
Clinical efficacy of meningoco ...... e months to five years of age.
@en
P2093
Hällström K
Jousimies H
Renkonen OV
P304
P356
10.1056/NEJM197709292971302
P407
P577
1977-09-01T00:00:00Z